Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2025 06:03 ET | Source: Research and Markets

Kidney Transplant Rejection Market Insight, Epidemiology and Market Forecast to 2034

Dublin, April 07, 2025 (GLOBE NEWSWIRE) -- The "Kidney Transplant Rejection - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. ...
October 24, 2024 10:14 ET | Source: Research and Markets

CD40 Agonists & CD40/Ligand Antagonists Pipeline Market Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "CD40 Agonists & CD40/L Antagonists Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
June 26, 2024 09:34 ET | Source: Research and Markets

Acute Graft-Versus-Host Disease Pipeline Research 2024 Featuring MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, and Incyte

Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Acute Graft-Versus-Host Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Acute...
May 28, 2024 06:38 ET | Source: Research and Markets

Graft versus Host Disease (GvHD) Pipeline Insights Report, 2024: Reveals 60+ Companies Engaged in Advancing 65+ Pipeline Drugs

Dublin, May 28, 2024 (GLOBE NEWSWIRE) -- The "Graft versus host disease - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. This report offers an in-depth look...
December 14, 2023 05:33 ET | Source: Research and Markets

Immunotherapy Advancements: CD40 Agonist and Antagonist Research Fuels Oncology and Autoimmunity Treatment Innovations

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "CD40 Agonists & CD40/L Antagonists Pipeline Review" report has been added to ResearchAndMarkets.com's offering. The global scientific community...
November 22, 2023 08:58 ET | Source: Research and Markets

Lerapolturev (Formerly Known as PVSRIPO) + Pembrolizumab for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecast Report, 2019-2023 & 2023-2032

Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...